

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58283 A1

- (51) International Patent Classification⁷: **A23L 1/305, A61K 31/195**
- (21) International Application Number: **PCT/NL01/00104**
- (22) International Filing Date: 8 February 2001 (08.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
1014380 14 February 2000 (14.02.2000) NL
- (71) Applicant (for all designated States except US): **FRIESLAND BRANDS B.V.** [NL/NL]; P.O. Box 226, NL-8901 MA Leeuwarden (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **VAN LEEUWEN, Paulus, Aluisius, Marie** [NL/NL]; Simon Carmiggeltlaan 1, NL-1187 VN Amstelveen (NL). **HOUDIJK, Alexander, Petrus, Johannes** [NL/NL]; Van der Ghiessenstraat 25, NL-1181 RS Amstelveen (NL). **GLAS, Cornelis** [NL/NL]; Woelwijk 3, NL-9255 KE Tietjerk (NL).
- (74) Agent: **JORRITSMA, Ruurd**; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/58283 A1

(54) Title: USE OF GLUTAMATE AND/OR A GLUTAMATE PRECURSOR FOR THE PREPARATION OF A NUTRITIONAL OR PHARMACEUTICAL PREPARATION FOR THE TREATMENT OR PREVENTION OF HYPERPERMEABILITY OR UNDESIRE PERMEABILITY OF THE INTESTINAL WALL

(57) Abstract: The present invention relates to the use of glutamic acid for the preparation of a nutritional preparation that is intended for use for the treatment or prevention of excess or undesired permeability of the intestinal wall. In particular, according to the invention the glutamic acid is used in a nutritional preparation, such as a baby food or an enteral food. Examples of conditions where glutamic acid is used are: food allergy, internal drug allergy, sepsis, low blood flow through the intestines, ICU patients, surgical interventions, malnutrition or intestinal maturation of newborn babies.

USE OF GLUTAMATE AND/OR A GLUTAMATE PRECURSOR FOR THE PREPARATION OF A
NUTRITIONAL OR PHARMACEUTICAL PREPARATION FOR THE TREATMENT OR PREVENTION OF
HYPERPERMEABILITY OR UNDESIRE PERMEABILITY OF THE INTESTINAL WALL

The invention relates to the preparation of a nutritional preparation that is suitable
for use in the case of conditions associated with an increased permeability of the intestinal
5 wall.

The intestinal epithelium acts as a selective barrier which allows the absorption of
nutrients but restricts the passage of microorganisms and undesired macromolecules.
Maintaining this barrier is considered to be important in order to protect the host against
the migration of pathogenic microorganisms from the intestines to the bloodstream. It is
10 assumed that the increase in the permeability of the intestines is associated with damage to
the paracellular transport system of the intestinal mucosa, as a result of which translocation
of endotoxins and (pathogenic) bacteria can occur. As a result of the damage to the
intestinal mucosa it is also possible for absorption of macromolecules to occur, which are
then able to initiate allergic reactions.

15 An increase in the permeability of the intestinal wall has been detected in clinical
conditions associated with damage to the intestinal mucosa barrier, such as endotoxaemia,
sepsis, multiple trauma, malnutrition, major surgical interventions, parenteral nutrition and
burns. An increase in the permeability to larger molecules, such as proteins, has been
found in the newborn, but also occurs in healthy people if they are allergic to food
20 products.

It is known that glutamine is able to lower the macromolecular hyperpermeability of
intestinal cells which is induced by phorbol 12,13-dibutyrate (Kouznetsova et al.
J. Parenteral Enteral Nutrition, **23** (1999) 136-139). A disadvantage of glutamine,
however, is that it is not stable at room temperature, which renders it unsuitable for (non-
25 chilled) foods with a long shelf life. Moreover, glutamine has poor solubility.

Instead of glutamine, specific products based on peptides, mainly di- and tripeptides,
are used. These peptides are frequently prepared from glutamine-rich vegetable proteins,
such as, in particular, wheat protein, in which preparation method, following enzymatic
conversion, fractionation technology is used in order to obtain the specific peptide fraction
30 as the main fraction. Examples thereof can be found in JP 05236909 and JP 08157385.
Such a preparation of these peptides is expensive and complex. Moreover, a product
obtained from wheat protein can be problematic for some patients, such as coeliac patients.

It has now been found that too high a permeability of the intestinal wall can be effectively treated or prevented by the administration of a suitable quantity of glutamate and/or a glutamate precursor, preferably in a nutritional preparation. The invention therefore relates to a nutritional or pharmaceutical preparation containing glutamate and/or a glutamate precursor, in particular for such a use, as described in more detail in the appended claims.

From the state of the art, for instance US 5,366,723 it is known to use a combination of glutamic acid, aspartic acid and cysteine in decreasing the toxicity of platinum compounds in the treatment of cancer. One of the activities mentioned is regeneration of the intestinal mucosa. However, regeneration of the intestinal mucosa relates to a different phenomena than permeability of the intestine which is in particular associated with integrity of the intestine or the paracellular transport via the intestinal mucosa.

Here a nutritional preparation is understood to be a composition that contains food constituents (at least one), such as proteins, carbohydrates, fats, vitamins, minerals and the like. Preferably the composition contains more than one food constituent and preferably it contains all necessary food constituents. It can therefore be a food supplement or a complete food or a food drug ("neutraceuticum").

The nutritional preparation of the invention can be an infant formula or children's food or an enteral (functional/clinical/problem solving) food.

Substances that are known to have a beneficial effect on the intestinal function (permeability) can also be added. In particular, one or more polyamines such as spermine, spermadine or putrescine or one or more polyamine precursors, in particular ornithin and arginin can be used. Such polyamines are, for example, described in Dorhout et al., *Br. J. Nutrition*, 1997, 639-654 and in a report of a seminar held on 29 June to 2 July 1999 in Glasgow, published in *Proceedings of the Nutrition Society*, Vol. 59 (Issue 1), 2000, 81-86. Polyamines or the precursors thereof can have a beneficial contribution in e.g. postnatal intestinal maturation, permeability of the intestine to macromolecules (allergy), the translocation of bacteria, etc.

The preparation contains preferably 0.05 to 10 g, more preferably 0.2 to 4 g free glutamate per 100 g of the nutritional preparation (dry weight). The polyamines are preferably present in an amount of 1 to 10 mg per 100 g of the nutritional preparation (dry weight).

The glutamate is preferably incorporated in a nutritional preparation alongside proteins or peptides, such as lactic or vegetable proteins. The nutritional preparation contains in particular lactic proteins or hydrolysates obtained therefrom. Lactic proteins comprise casein, whey proteins and lactoferrin.

5 Carbohydrates are understood to be digestible carbohydrates, such as glucose, lactose, maltose and sucrose, and digestible oligosaccharides and polysaccharides, such as maltodextrins, amylopectins and starch, as well as non-digestible carbohydrates (food fibres) such as galacto-oligosaccharides or fructo-oligosaccharides (inulin), vegetable and animal and microbial gums, such as carob bean flour and gum arabic. Fats comprise
10 vegetable and animal fats, fats with medium length chains (C_8 - C_{12}) (MCT), fats with unsaturated long chains (such as γ -linolenic acid, arachidonic acid, eicosapentaenoic acid and docosahexaenic acid).

The nutritional preparation according to the invention can also contain glutamine or an equivalent thereof. Glutamine equivalents are known to those skilled in the art.
15 Examples of these are the abovementioned dipeptides and tripeptides. If the nutritional preparation is a food for babies or toddlers, the weight ratio of glutamic acid : glutamine from the free amino acids is greater than 1 : 1, in particular greater than 5 : 1 and very particularly greater than 25 : 1.

Here a glutamate precursor is meant to include glutamic acid or alfa-keto glutaric
20 acid, a biochemical precursor. Glutamate can be in the form of a physiologically acceptable glutamate salt (for example the sodium, potassium, calcium or magnesium salt). As a source of glutamate protein hydrolysates can be used or freeze dried cultures of (lactic acid) bacteria (probiotics) which contain glutamate as a protecting agent. An example of such a lactic acid culture is *Lactobacillus Reuteri*, obtainable from Biogaia,
25 originating from human milk.

Free glutamic acid is understood to be glutamic acid or a salt thereof that is not bound in protein or peptide and that has either been added or is present in the free amino acid fraction of a protein or hydrolysed protein (hydrolysed proteins usually contain 10 - 20% free amino acids) or is present as a protecting agent in a probiotic lactic acid culture.

30 The preparations of the invention are preferably combined with suitable prebiotics and probiotics, which have a beneficial effect on the intestinal flora. The prebiotics comprise short or long chain oligosaccharides, in particular galacto-oligosaccharides and

fructo-oligosaccharides, branched oligosaccharides, sialyloligosaccharide, nucleotides, protein hydrolysates, sialic acid rich milk products or derivatives thereof, etc.

The nutritional preparation to be prepared according to the invention can be used in the treatment of all conditions where hyperpermeability of the intestinal wall is concerned.

- 5 Examples of these are food allergy, allergy to internal drugs, sepsis and similar clinical conditions, translocation of pathogenic bacteria through the intestinal wall, endotoxaemia, viral diarrhoea, low intestinal blood flow, IC patients, patients after surgical interventions or with major burns, parenteral nutrition and undernutrition. It can also be used in the case of intestinal maturation of newborn babies, reduction of abnormal crying in children or the
- 10 treatment of hyperactivity (Attention Deficit Hyperactivity Disorder, ADHD).

Example 1

The macromolecular permeability of the intestinal epithelium is controlled by the passage through intercellular tight junctions in the paracellular channels. Opening of these

15 tight junctions is controlled by the epithelial cells in response to various intercellular mediators, such as Ca, cyclic AMP, G proteins and protein kinase c. The human intestinal cell line HT-29CL.19A is becoming increasingly more important for studying this paracellular permeability in vitro. See also the abovementioned article in *J. Parenteral Enteral Nutrition*, that is incorporated herein by reference.

20 For the present examples, confluent monolayers of HT-29CL.19A cells were cultured on permeability filters. After 14 - 17 days the cells were allowed to grow for a further two days without glutamine in the medium. The transepithelial permeability from apical to basolateral was determined for horseradish peroxidase (HRP) with the aid of an enzyme assay. Phorbol 12,13-dibutyrate (PDB, 1 mmol/l) was used to increase the

25 permeability. The effect of glutamine, glutamate and the g-glutamyl transferase inhibitor acivicin was investigated. All agents were added to the apical compartment.

It was found that PDB increases the HRP flux 3-fold compared with the control after 150-279 min stimulation ($p < 0.001$). Glutamine reduces this hyperpermeability appreciably. Glutamate (0.6 mmol/l) had the same effect ($p < 0.001$). Acivicin prevented

30 the glutamine-mediated reduction in the hyperpermeability induced by PDB. This effect did not occur in the presence of glutamate.

It can be seen from this experiment that glutamate reduces the macromolecular

hyperpermeability in HT-29CL.19A cells.

Example 2

A complete, pulverulent, glutamic acid-containing baby food for premature children
5 was prepared which had the following composition per 100 g powder - dry matter:

| | | |
|----|----------------------------|--------|
| | desalinated whey, solids | 39.2 g |
| | vegetable fats | 26.4 g |
| | lactose | 17.9 g |
| | skimmed milk, solids | 13.4 g |
| 10 | glucose syrup | 0.90 g |
| | soy lecithin | 0.16 g |
| | glutamic acid | 0.5 g |
| | L-arginine | 0.05 g |
| | taurine | 0.04 g |
| 15 | L-Tryptophane | 0.02 g |
| | nucleotides | 0.03 g |
| | microminerals and vitamins | 1.4 g |
| | casein/whey protein ratio | 40/60 |
| 20 | % crude protein | 10.8 |
| | % free glutamic acid | 0.5 |

A fluid composition that contains approximately 15% solids can be prepared from
such a powder. Approximately 175 ml of the fluid composition is administered per kg
25 body weight per day.

Example 3

A food was prepared as in example 2, with the exception that instead of 0.7 g lactose
0.7 g galacto-oligosaccharides were incorporated per 100 g powder.

30

Example 4

A complete, pulverulent, glutamic acid-containing baby food for children with an

allergy was prepared which had the following composition per 100 g powder - dry matter:

| | | |
|----|----------------------------|---------|
| | hydrolysed casein | 13.5 g |
| | vegetable fat | 27 g |
| | glucose syrup | 58.05 g |
| 5 | taurine | 0.04 g |
| | L-carnitine | 0.01 g |
| | microminerals and vitamins | 1.4 g |
| | % crude protein | 12 |
| 10 | % free ornithin | 0.01 |
| | % free glutamic acid | 0.3 |

Example 5

A food was prepared according to example 4, with the exception that 0.25 g arginin
15 and 0.005 g spermine and spermidine was incorporated instead of 0.255 g glucose syrup.

Example 6

A pulverent food for young children was prepared to limit excessive crying which
contained per 100 gram:

| | | |
|----|--|-----------------|
| 20 | lactic protein | 11 g |
| | fat | 27 g |
| | lactose | 56 g |
| | nucleotides | 0.03 g |
| 25 | glutamic acid | 0.45 g |
| | minerals, vitamins, probiotic | 3.02 g |
| | water | 2.5 g |
| | ratio whey protein : casein : casein hydrolysate | 40:30:30 |
| 30 | L. Reuteri (Biogaia) | 1×10^8 |
| | % free glutamic acid | 0.5 |

Example 7

A pulverent food for older children with multiple functional properties was prepared, containing per 100 grams:

5

lactic protein 22.1 g

fat 18.4 g

lactose 39 g

sucrose 10 g

10 alfa-ketoglutarate 0.1 g

fructo-oligosaccharide (inulin) 3 g

nucleotides 0.05 g

minerals, vitamins, probiotics 4.85 g

water 2.5 g

15

L. Reuteri (Biogaia) 1×10^8

casein/whey protein ratio 75:25

20 goat's milk protein (comprising human-milk like sialyloligosaccharides) : 20 % of the lactic protein

% alfa-ketoglutarate 0.1

% free glutamic acid 0.05

% free glutamic acid equivalents 0.15

25

Example 8

A pulverent food for children having hyperactivity syndrome (ADHD) was prepared containing, compared to example 7, a casein/casein hydrolysate ratio in the lactic protein fraction of 40:60.

30

The product contains per 100 g

L. Reuteri 1×10^8

% free glutamic acid equivalents 0.45

Example 9

A problem-solving, fluid, glutamic acid-containing enteral food based on caseinate and glutamine-rich vegetable hydrolysed protein (30% glutamine) was prepared which had

5 the following composition per 100 g:

| | | |
|----|-----------------------------------|--------|
| | caseinate | 5.2 g |
| | glutamine-rich hydrolysed protein | 1.0 g |
| | glutamic acid | 0.6 g |
| | arginine | 0.2 g |
| 10 | fats | 3.4 g |
| | carbohydrates | 9.5 g |
| | minerals and vitamins | 0.4 g |
| | lecithin | 0.1 g |
| | water | 79.6 g |
| 15 | | |
| | % crude protein | 6.3 g |
| | % free arginin | 0.2 g |
| | % glutamin | 0.3 g |
| | % free glutamic acid | 0.6 g |

Claims

1. Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall.
2. Use according to claim 1, wherein the nutritional preparation is an infant formula or children's food.
3. Use according to claim 1 or 2, wherein the nutritional preparation is an enteral food or a food supplement.
4. Use according to any one of claims 1 to 3, wherein the nutritional preparation also contains lactic proteins or hydrolysed lactic proteins.
5. Use according to any one of claims 1 to 4, wherein the nutritional preparation also contains vegetable proteins or hydrolysed products thereof.
6. Use according to any one of claims 1 to 5, wherein hydrolysed protein is used as the source of glutamate.
7. Use according to any one of claims 1 to 6, wherein the glutamate precursor is glutamic acid or alfa-keto glutaric acid.
8. Use according to any one of the preceding claims, wherein the nutritional preparation also contains glutamine or an equivalent thereof.
9. Use according to claim 8, wherein the weight ratio of glutamic acid : glutamine in the free amino acid fraction is greater than 1 : 1, in particular greater than 5 : 1 and preferentially greater than 25 : 1.
10. Use according to any one of the preceding claims, wherein the preparation further

contains one or more polyamines. in particular spermine, spermidine or putrescine and/or one or more polyamine precursors, in particular ornithin and arginin.

11. Use according to any one of the preceding claims, wherein the nutritional
5 preparation contains 0.05 - 10 g, preferably 0.2 - 4 g free glutamate per 100 g nutritional preparation (dry weight).
12. Use according to any one of the preceding claims, wherein the nutritional
10 preparation further contains one or more prebiotics, preferably selected from the group consisting of protein hydrolysates, nucleotides, galacto-oligosaccharides, fructo-oligosaccharides, branched oligosaccharides and sialyloligosaccharides or equivalents thereof.
13. Use according to any one of the preceding claims, wherein the nutritional
15 preparation contains freeze dried probiotics, in particular freeze dried *Lactobacillus Reuteri* as the source of glutamate.
14. Use according to any one of the preceding claims, in the case of deterioration of the
20 mucosal barrier, intestinal dysfunction or injury, suboptimal intestinal wall maturation of new-borns, undernutrition, suboptimal intestinal blood flow, allergy, sepsis, translocation of pathogenic bacteria through the intestinal wall, endotoxaemia, viral diarrhoea, regularly crying children, hyperactive children, IC patients, patients after surgery or major burns.
15. Preparation containing free glutamate and/or a glutamate precursor and polyamines,
25 in particular spermine, spermidine or putrescine and/or one or more polyamine precursors, in particular ornithin and arginin.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 01/00104

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23L1/305 A61K31/195

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|--------------------------------------|
| X | <p>RAUL FRANCIS ET AL: "Functional and metabolic changes in intestinal mucosa of rats after enteral administration of ornithine alpha-ketoglutarate salt." JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, vol. 19, no. 2, 1995, pages 145-150, XP001001310 ISSN: 0148-6071 page 145; table 1 page 146</p> <p style="text-align: center;">--- -/--</p> | <p>1,3,7,8, 10,12, 14,15</p> |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

18 May 2001

Date of mailing of the international search report

28/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Heezius, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/NL 01/00104

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|---------------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | <p>EWIUSHIK A L ET AL: "Performance and intestinal development of piglets receiving diets supplemented with selected amino acids or polyamines." CANADIAN JOURNAL OF ANIMAL SCIENCE, vol. 77, no. 4, December 1997 (1997-12), pages 741-742, XP001001415 1997 Annual Meeting of the Canadian Society of Animal Science ISSN: 0008-3984 the whole document ---</p> | 1,3,5, 11,12, 14,15 |
| X | <p>DATABASE WPI Section Ch, Week 199342 Derwent Publications Ltd., London, GB; Class B04, AN 1993-330544 XP002148350 & JP 05 236909 A (SNOW BRAND MILK PROD CO) cited in the application abstract ---</p> | 1,3,5-8, 12,14,15 |
| X | <p>PATENT ABSTRACTS OF JAPAN vol. 1996, no. 10 & JP 08 157385 A (KIRIN BREWERY) cited in the application abstract ---</p> | 1,3,5-8, 12,14,15 |
| X | <p>US 5 366 723 A (TULOK ISTVAN) 22 November 1994 (1994-11-22) claims 7,10 ---</p> | 1,3 |
| A | <p>US 5 981 590 A (GEWOLB IRA H ET AL) 9 November 1999 (1999-11-09) column 3, line 21 - line 29 claims 1,3,5,14 -----</p> | 1-15 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/NL 01/00104

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| JP 05236909 A | 17-09-1993 | JP 2524551 B | 14-08-1996 |
| JP 08157385 A | 18-06-1996 | NONE | |
| US 5366723 A | 22-11-1994 | NONE | |
| US 5981590 A | 09-11-1999 | NONE | |